Nelusha Amaladas

647 total citations
7 papers, 48 citations indexed

About

Nelusha Amaladas is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nelusha Amaladas has authored 7 papers receiving a total of 48 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nelusha Amaladas's work include Cancer Immunotherapy and Biomarkers (4 papers), RNA modifications and cancer (2 papers) and Fibroblast Growth Factor Research (2 papers). Nelusha Amaladas is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), RNA modifications and cancer (2 papers) and Fibroblast Growth Factor Research (2 papers). Nelusha Amaladas collaborates with scholars based in United States. Nelusha Amaladas's co-authors include Gerald E. Hall, David Surguladze, Bronislaw Pytowski, Aik Choon Tan, Michael Kalos, Juan C. Hernandez‐Prera, José R. Conejo-García, Jason R. Manro, Robbert J.C. Slebos and Gregory D. Plowman and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Nelusha Amaladas

7 papers receiving 47 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nelusha Amaladas United States	4	28	25	14	10	8	7	48
Sandra Re United States	4	38 1.4×	21 0.8×	9 0.6×	15 1.5×	10 1.3×	6	52
Marta Casarrubios Spain	4	27 1.0×	15 0.6×	14 1.0×	9 0.9×	13 1.6×	5	43
Shusuke Kawashima Japan	4	32 1.1×	22 0.9×	28 2.0×	8 0.8×	8 1.0×	6	61
Maartje G. Schouwenburg Netherlands	4	36 1.3×	20 0.8×	15 1.1×	16 1.6×	8 1.0×	5	52
Paul Farrington United Kingdom	3	30 1.1×	27 1.1×	16 1.1×	7 0.7×	6 0.8×	4	51
Ani K. Stoyanova Germany	3	12 0.4×	25 1.0×	15 1.1×	6 0.6×	8 1.0×	6	45
Syed Muhammad Fahmy Alkaff Singapore	2	29 1.0×	17 0.7×	9 0.6×	6 0.6×	16 2.0×	2	42
Giovanni Valenti Germany	3	50 1.8×	23 0.9×	34 2.4×	11 1.1×	9 1.1×	3	79
Naveen Shridhar United Kingdom	5	21 0.8×	21 0.8×	19 1.4×	8 0.8×	7 0.9×	7	54
Ayse N. Menevse Germany	4	43 1.5×	24 1.0×	26 1.9×	14 1.4×	5 0.6×	4	65

Countries citing papers authored by Nelusha Amaladas

Since Specialization

Citations

This map shows the geographic impact of Nelusha Amaladas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nelusha Amaladas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nelusha Amaladas more than expected).

Fields of papers citing papers by Nelusha Amaladas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nelusha Amaladas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nelusha Amaladas. The network helps show where Nelusha Amaladas may publish in the future.

Co-authorship network of co-authors of Nelusha Amaladas

This figure shows the co-authorship network connecting the top 25 collaborators of Nelusha Amaladas. A scholar is included among the top collaborators of Nelusha Amaladas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nelusha Amaladas. Nelusha Amaladas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Li, Yanxia, Nelusha Amaladas, Jason R. Manro, et al.. (2022). Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models. PLoS ONE. 17(7). e0268244–e0268244. 11 indexed citations

Chaudhary, Ritu, Robbert J.C. Slebos, Feifei Song, et al.. (2020). Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. Molecular Carcinogenesis. 60(2). 138–150. 16 indexed citations

Chaudhary, Ritu, Robbert J.C. Slebos, Feifei Song, et al.. (2020). Effects of prexasertib, a CHK1 inhibitor, in the immune microenvironment of head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology. 38(15_suppl). e18541–e18541. 1 indexed citations

Surguladze, David, Xiaodi Ren, Alan S. Rigby, et al.. (2019). Abstract 4835: LY3076226, a novel anti-FGFR3 antibody drug conjugate exhibits potent and durable anti-tumor activity in tumor models harboring FGFR3 mutations or fusions. 4835–4835. 1 indexed citations

Surguladze, David, Alan C. Rigby, Paul Balderes, et al.. (2019). Abstract 4835: LY3076226, a novel anti-FGFR3 antibody drug conjugate exhibits potent and durable anti-tumor activity in tumor models harboring FGFR3 mutations or fusions. Cancer Research. 79(13_Supplement). 4835–4835. 8 indexed citations

Novosiadly, Ruslan D., David Schaer, Nelusha Amaladas, et al.. (2018). Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms. Cancer Research. 78(13_Supplement). 4549–4549. 8 indexed citations

Novosiadly, Ruslan D., David Schaer, Zhen Lu, et al.. (2017). P3.07-006 Pemetrexed Exerts Intratumor Immunomodulatory Effects and Enhances Efficacy of Immune Checkpoint Blockade in MC38 Syngeneic Mouse Tumor Model. Journal of Thoracic Oncology. 12(11). S2300–S2300. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact